Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy

Fig. 2

Pembrolizumab response and survival were independent of initial edema:tumor volumes and concordant with edema change. a Pre-treatment BM edema:tumor volume ratio does not impact response to pembrolizumab (PD-progression of disease, SD-stable disease, PR-partial response, and CR-complete response, by modified RECIST version 1.1). b Tumor and edema volume changes from baseline after 4 cycles of pembrolizumab were strongly correlated. As pembrolizumab-sensitive BMs shrank, the tumor-associated edema also shrank and vice-versa for pembrolizumab-resistant tumors. Due to the wide range in values, the log percent change was used for graphical presentation. c Kaplan-Meier survival curves show no significant difference between BM PFS in patients whose edema:tumor volume was above the median compared to those whose ratio was below the median; d overall survival of NSCLC and melanoma patients was similarly not affected by baseline edema:tumor volume ratios

Back to article page